FDA’s Sentinel Likely To Outpace Traditional Post-Market Studies, But Will It Replace Them?
This article was originally published in The Pink Sheet Daily
Executive Summary
Pilot project for overactive bladder drug Mybretriq raises questions as to how Sentinel will affect sponsor’s risk-monitoring obligations.
You may also be interested in...
FDA Sentinel Transition Will Involve Expanding Rx Safety Data Sources
Moving Mini-Sentinel pilot program to a fully operational and sustainable Sentinel postmarket safety surveillance system will take place over next year, CDER Director Woodcock says.
Adverse Event Reports Rising Faster Than FDA Adds Surveillance Staff
Adverse event reports submitted each year have quadrupled over the last decade, and FDA expects the reports to retain their value in ensuring product safety even as more technology helps with drug safety monitoring.
Adverse Event Reports Rising Faster Than FDA Adds Surveillance Staff
Adverse event reports submitted each year have quadrupled over the last decade, and FDA expects the reports to retain their value in ensuring product safety even as more technology helps with drug safety monitoring.